Logo Mark
Publications

Non-clinical Imetelstat

All Publications

Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in vitro and increases survival in vivo in acute myeloid leukemia

ImetelstatNon-clinical Imetelstat
AACR 2017

Rusbuldt JJ, et al.

Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis

ImetelstatNon-clinical Imetelstat
Leukemia 2017

Mosoyan G, et al.

The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts

ImetelstatNon-clinical Imetelstat
ASH 2016

Bruedigam C, et al.

Telomerase Inhibition with Imetelstat Eradicates β-catenin Activated BC CML Stem Cells

ImetelstatNon-clinical Imetelstat
ASH 2016

Ma W, et al.

Myelosuppression in Patients Treated With the Telomerase Inhibitor Imetelstat is Not Mediated Through Activation of Toll-Like Receptors

ImetelstatNon-clinical Imetelstat
AACR 2016

Baerlocher GM, et al.

Impact of Hypomethylating Agents on hTERT Expression and Synergistic Effect in Combination With Imetelstat, a Telomerase Inhibitor, in Acute Myeloid Leukemia Cell Lines

ImetelstatNon-clinical Imetelstat
AACR 2016

Rusbuldt J, et al.

Imetelstat (GRN163L), a Telomerase Inhibitor Selectively Affects Malignant Megakaryopoiesis in Myeloproliferative Neoplasms (MPN)

ImetelstatNon-clinical Imetelstat
ASH 2014

Iancu-Rubin C, et al.

Effects of Imetelstat on CD34+ Cells of Patients with Myelofibrosis

ImetelstatNon-clinical Imetelstat
ASH 2014

Wang X, et al.

Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy

ImetelstatNon-clinical Imetelstat
Cell Stem Cell 2014

Bruedigam C, et al.

Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals

ImetelstatNon-clinical Imetelstat
ASH 2011

Brunold C, et al.

[facetwp facet="publication_load_more"]